Evofosfamide

Phase 2Small molecule

Merck & Co.

Evofosfamide is one of 42 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerNot yet recruiting

ALSRecruiting

Prostate CancerPhase 2

Not yet recruiting

ALSPhase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Antiandrogen Therapy

UUniversity of Washington

Phase 3

10 2

Piflufolastat

Novartis

Phase 3

2 3

AAA817

Novartis

Phase 3

1 4

Gallium Ga 68 Gozetotide

MMayo Clinic

Phase 3

3 5

Piflufolastat F 18

Novartis

Phase 3

1 6

SHR3680

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

5 7

Trexall

Evofosfamide

1 9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Recruiting

ALS

NCT06782555

Q2 2030

Phase 2Not yet recruiting

Prostate Cancer

NCT06836726

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01833546·20 enrolled

ALS1 trial

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

Recruiting·IImmunoGenesis·Phase 1/2·NCT06782555·71 enrolled

Prostate Cancer1 trial

Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

Not yet recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06836726·35 enrolled

Immunotherapy1 trial

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Unknown status·TThreshold Pharmaceuticals·Phase 1·NCT03098160·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Evofosfamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Evofosfamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Evofosfamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Evofosfamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2030

Trials by Indication[1]

Pancreatic Cancer1 trial

ALS1 trial

Prostate Cancer1 trial

Immunotherapy1 trial

References

Drug Info

Quick Facts

Related News